XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
"ICH Q3A(R2) sets reporting, identification, and qualification thresholds for drug substance impurities that have been in force since 2006. Nearly two decades later, the most common impurity-related deficiency FDA issues is not a failure
View details →
The CMC package FDA receives is not evaluated solely on the science it contains — it is evaluated on whether the scientific narrative is coherent, internally consistent, and written in a way that allows
View details →
The specification table in 3.2.S.4.1 is the single most scrutinized document in a drug substance CMC submission. Every limit must be scientifically justified, every method must be validated to demonstrate it can meet the
View details →
CAR-NK cell therapy solves the most significant commercial limitation of CAR-T: patient specificity. An allogeneic CAR-NK product can be manufactured from a single cord blood unit, expanded to thousands of doses, cryopreserved, and shipped
View details →
An engineered bacterium that produces a therapeutic protein inside the patient's gut is simultaneously a live biotherapeutic product, a gene-therapy-adjacent vector, and a local drug delivery system. It has no single clear FDA regulatory
View details → ICH Q13 was finalized in 2022. FDA issued its implementation guidance in 2023. The Emerging Technology Program has been accepting continuous manufacturing applicants for over a decade. And yet the deficiency letter pattern for
View details → Continuous bioprocessing delivers higher volumetric productivity than fed-batch, a smaller facility footprint, and improved quality attribute consistency from steady-state operation. The biopharmaceutical industry knows this. FDA's biologics reviewers know this. And yet the BLA
View details → Process Analytical Technology has been an FDA regulatory priority since 2004. The PAT guidance was published two decades ago. ICH Q8, Q10, and Q13 all reference PAT as a cornerstone of the modern quality
View details → ICH Q8(R2) was finalized in 2009. ICH Q11 was published in 2012. Fifteen-plus years of regulatory infrastructure for Quality by Design, and the biologics BLA failure mode for QbD submissions has not changed: the
View details →
Every pharmaceutical quality director knows that Stage 3 Continued Process Verification requires ongoing process monitoring using statistical methods — FDA's 2011 Process Validation Guidance says this explicitly. And every pharmaceutical manufacturing site has implemented
View details →
Mechanistic and hybrid process models are now routine in pharmaceutical process development — population balance models for granulation and crystallization, computational fluid dynamics for mixing scale-up, first-principles droplet evaporation models for spray drying. FDA
View details →
The pharmaceutical industry has been implementing electronic batch records for more than two decades. 21 CFR Part 11 was issued in 1997. FDA's predicate rule for batch records — 21 CFR 211.188 — has
View details → Dissolution testing is the most frequently performed analytical test in pharmaceutical quality control. Every oral drug product has a dissolution specification. But for modified-release oral drug products — extended release, delayed release, gastro-retentive —
View details → Pharmaceutical manufacturing has invested heavily in Pharma 4.0: process historians capturing millions of data points per batch, manufacturing execution systems tracking every material movement and operator action, LIMS integrating in-process and release testing data
View details → The original ICH Q9(R1) guideline for quality risk management was issued in 2005. The pharmaceutical industry adopted FMEA as the standard QRM tool, built risk assessments into CMC process characterization, design space definition, and
View details → Design of Experiments is the foundation of modern pharmaceutical process characterization, and every CMC team running DOE studies for a design space submission believes their methodology is sound. The deficiency letters tell a different
View details →
Every gene therapy program reaches a scale-up decision point where the research process — T-flask, serum-containing media, research-grade reagents, milligram-scale purification — must become a GMP manufacturing process capable of producing clinical and commercial
View details → Single-use bioreactors, single-use mixing bags, and single-use filling systems have become the infrastructure standard for biopharmaceutical manufacturing. The adoption rate is high and the operational advantages are well-documented. What is less well-documented is the
View details →